Blackrock Neurotech unveils next-generation BCI interface

[Image from Milad Fakurian on Unsplash]Blackrock Neurotech announced today that it revealed its Neuralace next-generation neural interface for brain-computer interface (BCI) technology.

Salt Lake City-based Blackrock unveiled the interface at the Society for Neuroscience 2022 event this week.

It designed the Neuralace platform as an ultra-high channel count, flexible electrode. The company said in a news release that it provides a glimpse into the technology set to fuel its future BCIs.

“Neuralace demonstrates our belief in where the science must go in order to unlock the true potential of BCI,” said Marcus Gerhardt, co-founder and CEO of Blackrock. “This concept technology is the start of Blackrock’s journey toward whole-brain data capture that will transform the way neurological disorders are treated.”

Building upon established technology

Blackrock develops the NeuroPort Array neural interfacing system. The system, use…

Read more
  • 0

Alcon stock rises on Q3 EPS beat

Alcon (NYSE:ALC) shares ticked up this morning on third-quarter results that came in ahead of the consensus earnings forecast.

Shares of ALC rose 8% at $68.46 apiece as the market opened today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — rose 6.9%.

The Geneva, Switzerland-based company posted profits of $116 million for the quarter. That amounts to 23¢ per share on sales of $2.124 billion for the three months ended Sept. 30, 2022.

Alcon recorded a massive bottom-line gain from profits of just $2 million this time last year. It posted sales growth of 1.9%.

Adjusted to exclude one-time items, earnings per share came in at 50¢. That just beat out expectations of 48¢ on Wall Street. Sales just missed as analysts projected revenues of $2.13 billion.

The company’s surgical business sales grew by 5% year-over-year. Alcon attributed this to improvements in international …

Read more
  • 0

Illumina is cutting 5% of its workforce

Illumina (Nasdaq:ILMN) announced that it commenced a headcount reduction totaling approximately 5% of its global workforce.

The company said yesterday that it is proactively realigning its core operating expenses in response to the current macroeconomic environment. It seeks to maintain its focus on its innovation roadmap and sustainable long-term growth, according to an SEC filing.

Get the full story at our sister site, Drug Discovery & Development.

Read more
  • 0

Cardinal Health wants to bring hospital-level care into the home

Cardinal Health (NYSE: CAH) announced today that it is launching a pilot chain supply chain network to enable hospital-level healthcare in people’s homes.

The Dublin, Ohio–based medical device and pharmaceuticals supplier is launching the Velocare supply chain network and last-mile fulfillment service through a strategic partnership with Boston-based Medically Home. Early this year, Cardinal Health joined Baxter, Global Medical Response, the Mayo Clinic and Kaiser Permanente to invest $110 million in Medically Home.

Under the strategic collaboration, Cardinal Health at-Home Solutions is now supporting a Medically Home health system customer with Velocare.

More about Cardinal Health’s Velocare

Cardinal Health already had capabilities including global logistics and distribution expertise. In addition, it manages a large network of suppliers and vendors. Also, it has access to a wide range of home-based care providers.

The Velocare pilot …

Read more
  • 0

Tandem stock ticks up after Wells Fargo upgrade

Tandem Diabetes Care (Nasdaq:TNDM) shares ticked up today after Wells Fargo declared it “Equal Weight,” an improvement from “Underweight.”

Shares of TNDM rose 8.3% at $42.81 apiece in midday trading today. MedTech 100 Index — which includes stocks of the world’s largest medical device companies — ticked up 6.8%.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

ResMed partners with Verily on digital health for sleep disorders

ResMed and Google’s sister company Verily recently launched a digital health joint venture called Primasun.

The companies launched the joint venture on Nov. 13 during HLTH 2022 in Las Vegas. They said Primasun will combine advanced healthcare technology and research into one comprehensive digital health platform. It will work with employers and healthcare providers to identify populations at risk of sleep disorders. After that, it will connect patients to certified sleep physicians.

“Sleep is the foundation of physical and mental health, and at Primasun, we believe there’s an opportunity to build a more efficient, equitable healthcare solution that helps patients clinically improve their sleep, and in turn, their quality of life,” said Primasun CEO Jonathon Lobbins. Most recently, Lobbins was VP of strategy and business development at Siemens Healthineers.

Initially, Primasun is offering a product that connects patients with certi…

Read more
  • 0

FDA clears Neocis surgical robot for bone reduction

The Yomi surgical robot. [Image from Neocis]Neocis announced today that it received FDA 510(k) clearance for its Yomi surgical robot system for use in guided bone reduction.

This represents the second FDA clearance for Neocis this year, and its 14th in total.

Miami-based Neocis designed its Yomi surgical robot for dental surgery. It assists clinicians in the planning and operative phases of dental implant placement. For example, Yomi offers interactive digital planning software and physical guidance for surgical instrumentation.

The new indication for Yomi allows dental professionals to perform robot-guided alveoloplasty of the mandible and/or maxilla. This is commonly referred to as bone reduction, according to a news release.

A CT scan of the patient digitally plans the bone reduction and placement of implants. During the procedure, Yomi’s guide arm provides haptic feedback. This keeps the burr from deviating beyond …

Read more
  • 0

Conmed pulls 2022 guidance due to software implementation

Conmed (NYSE:CNMD) announced today that it is withdrawing its full-year outlook over problems implementing software at its main distribution facility.

Largo, Florida-based Conmed last month issued its guidance with a reduction from previous projections. This came on the back of an underwhelming third-quarter performance that saw its stock dip by nearly 8%. However, shares of CNMD have been on the rise since then.

CNMD shares ticked up 1.3% at $90.24 apiece in midday trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was up more than 6%.

More about Conmed pulling is 2022 guidance

In October, the company cut its now withdrawn guidance for the full year, with the high end of its EPS expectations falling particularly far. It projected adjusted EPS to fall between $3.21 and $3.28. The company previously projected a range of $3.25 to $3.45. However, the low end of its revenue guidance rose. T…

Read more
  • 0

Penumbra launches VR-based rehab platform

The REAL y-Series full-body, non-tethered immersive healthcare offering for rehabilitation. [Image from Penumbra]Penumbra (NYSE:PEN) announced today that it launched a full-body, non-tethered immersive healthcare offering for rehabilitation.

Alameda, California–based Penumbra designed its REAL y-Series product with lower and upper body sensors. They allow clinicians to track full-body movement and progress in real-time.

By expanding its virtual reality-based immersive healthcare platform, Penumbra plans to support a broad range of patients. According to a news release, these patients undergoing physical or occupational therapy could improve their physical, cognitive and mental well-being.

“Two of the largest challenges in rehabilitation are maintaining patient motivation and lack of engagement,” said Gita Barry, EVP and GM of Penumbra’s Immersive Healthcare business. “Penumbra’s latest REAL y-series is the only hands-free, sensor-based VR platform available…

Read more
  • 0

Insulet issues device correction on Omnipod 5 controller due to charging issue

Insulet’s Omnipod 5 with the Dexcom G6 CGM. [Image from Insulet]Insulet (Nasdaq:PODD) announced a medical device correction for its Omnipod 5 automated insulin delivery system.

Acton, Massachusetts-based Insulet’s correction relates to an issue with the Omnipod 5 controller’s charging port and cable. The correction does not impact the Omnipod 5 pod, the previous-generation Omnipod Dash and Omnipod, or compatible Android smartphone devices with the Omnipod 5 app installed.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Medtronic launches 7-day infusion set for insulin pumps in U.S.

[Image from Medtronic]Medtronic (NYSE:MDT) announced today that it launched its Medtronic Extended Infusion set for seven-day wear with insulin delivery.

The Medtronic Extended Infusion Set represents the first and only infusion set labeled for wearing of up to seven days. The infusion set for delivering insulin from a pump to the body typically requires changing every two to three days. It is available exclusively for customers using MiniMed 600 and 700 series pumps. Medtronic developed it in partnership with Convatec Infusion Care.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Pear Therapeutics posts mixed bag Q3, cuts 22% of workforce

Pear Therapeutics (Nasdaq:PEAR) shares rose after hours on mixed third-quarter results compared to the consensus forecast.

The company also announced a large set of layoffs, following a previous workforce reduction in July.

Shares of PEAR rose 7.1% at $2.70 apiece after the market closed today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished today up 5.8%.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0